Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
What made us buy IEX@193, Tata Power@56, Titan@330, Divis@629, Persistent@700.
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Bafna Pharmaceuticals Ltd Stock Analysis

Small Cap
Evaluated by 440 users | BSE: 532989 | NSE: BAFNAPH |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 7.06%6.1%6.76%6.89%11.14%-2.55%-8.09%-30.74%-23.68%-3.17%9.65%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 10112416717814385.36547.243.642.571.289
Y-o-Y Gr. Rt.-22.4%34.8%6.2%-19.7%-40.1%-23.9%-27.4%-7.5%-2.7%67.7%-
Adjusted EPS (Rs.) 1.841.051.281.54.38-6.56-10.05-15.94-8.34-8.392.353.38
Y-o-Y Gr. Rt.--42.9%21.9%17.2%192%-249.8%NANANANANA-
Book Value per Share (Rs.) 28.8529.6931.1132.6438.3931.4821.9617.138.79-18.642427.46
Adjusted Net Profit 3.21.92.42.88.2-12.2-18.8-37.7-19.7-25.68
Net Op. Cash Flow (Rs. Cr.) -6.427.635.40.89.5-319.8-7.1-1.1-34.3-13.6-
Debt to Cash Flow from Ops -8.032.932.57129.136.73-27.074.17-6.56-42.22-0.09-1.12-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Bafna Pharmaceuticals Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales -6%-3.6%14.7%67.7%
Adjusted EPS 9.4%NANANA
Book Value per Share -2.3-5.311.90
Share Price 12.8% 31.5% 108.8% 28.4%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) 6.743.263.634.1211.64-18.68-35.91-88.23-64.35-5.5310.3213.14
Operating Profit Margin (%) 11.3215.1712.6913.1517.973.76-8.03-74.38-29.753.0214.5117.52
Net Profit Margin (%) 3.171.551.431.585.74-14.35-28.86-79.96-45.22-4.677.88.98
Debt to Equity 1.011.481.571.630.891.372.011.152.22-0.680.270.05
Working Capital Days 211301303304336490603721682459193172
Cash Conversion Cycle 73977710415224729023631340105
Loading price chart...
Entity Percentage Holding
Promoters 90.40%
Non-Institutions 9.60%
Pledged *51.0451.0451.0450.9650.961.451.451.470.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Bafna Pharmaceuticals Ltd's earnings have grown by 0%, whereas share price has appreciated 31.5% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Bafna Pharmaceuticals Ltd share price has appreciated 12.8% annually (CAGR) over the past ten years.

Data is not available for this company.

Bafna Pharmaceuticals was incepted by Bafna Mahaveer Chand in 1981 as a proprietary concern. It was converted into a public limited company on 28th march 1995. The company started its own manufacturing unit in October 1984.

Bafna Pharmaceuticals started its production with tablets facility and subsequently added capsule and oral syrup facilities respectively. BAFNA always focused on institutional and generic supply to keep its production line busy. It also concentrated on

Bafna Pharmaceuticals was incepted by Bafna Mahaveer Chand in 1981 as a proprietary concern. It was converted into a public limited company on 28th march 1995. The company started its own manufacturing unit in October 1984.

Bafna Pharmaceuticals started its production with tablets facility and subsequently added capsule and oral syrup facilities respectively. BAFNA always focused on institutional and generic supply to keep its production line busy. It also concentrated on registering its products in the international market.

The present manufacturing facilities of BAFNA is set up at Chennai. The facility for producing Betalactam products was constructed in the year 2001 in a separate block.

It acquired 2.65 acres of factory land in Grantylon village, near Chennai to expand its operations to regulated market like US and UK and also to manufacture its own products.

The company’s vision is to become a leading professionally run global pharma company setting standards across the pharma value chain.

Product Range:

  • Antibacterials
  • Antipyretics
  • Antconvulsants
  • Anxiolytics
  • Pain management
  • Anthelmintics
  • Antifungal
  • Appetite stimulants
  • Antidiarrhoeals
  • Antiemetics
  • Hypnotics
  • Antacids and antiulcerants
  • Vitamin and dietery preparation
  • Cough and cold preparations
  • Antiasthmatics
  • Calcium preparations
  • Antihypertensives
  • Antidiabetics

Achievements/ Awards:

  • BAFNA was awarded the WHO GMP in the year 1995.
  • Bagged the ‘Best Supplier Award’ from the State Pharmaceutical Corporation of Sri Lanka on 30th July 2005.
  • Accorded the status of an ‘Export House’ in recognition of its excellent export performance.
  • Received Medicines and Health Care Products Regulatory Agency (MHRA) approval for its Grantlyon facility meant for exports to the UK markets. Bafna was the 35th company in the Indian pharmaceuticals industry (IPI) to receive MHRA approval.
  • 2009 ISO 9001: 2000 Certificate of Registration for Manufacture and Export of Pharmaceutical products
  • MHRA Certificate of GMP Compliances of Manufacturer from Medicines and Healthcare products Regulatory Agency, U.K.
  • 2010 Bafna Pharmaceuticals have been awarded the Gold Quality Excellence Award 2009
  • Bafna Pharmaceuticals have inaugurated its Formulation Research & Development unit (Formulation Facility) in Chennai
  • 2011 Bafna Pharmaceuticals has received Indian Drug Manufacturer's Association (IDMA) Quality Excellence Award 2010 - Silver Award under the category of Formulations Units
  • Bafna Pharmaceuticals has received Udyog Rattan Award and Excellence Award from the Institute of Economic Studies Delhi.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback